THE DEAL, AT A GLANCE
From the announcementAkeso
01Who is involvedBacked by VariousFrom the announcement
Summarized from the deal record's source announcement; not yet independently reviewed.
Read the announcement ↗02What happenedAkeso raised $200M Growth RoundFrom the announcement
Summarized from the deal record's source announcement; not yet independently reviewed.
Read the announcement ↗03Why it mattersAkeso is using $200M of Growth Round financing to advance a PD-1/VEGF bispecific cancer immunotherapy into US clinical trials, positioning the company around drugs…From the announcement
Summarized from the deal record's source announcement; not yet independently reviewed.
Read the announcement ↗Click a part to explore its evidence. Unsupported imagery is withheld rather than guessed.Original record source ↗
Akeso · Financing Record
Explore source-linked visual explanations for Akeso. Unsupported claims are withheld while source review continues.
Record 681 · Recorded date: Needs review
What it does
Unsupported business claims are withheld pending source review. Explore the linked records for available evidence.
Explore company records →